HPS Pharmacies wish to advise that Janssen-Cilag have given notice of an interruption in supply of Caelyx® (doxorubicin liposomal) injection. Current stock holdings are expected to be exhausted late in October, and it is not yet known when supply will resume.
This shortage is due to manufacturing difficulties which do not affect the safety or quality of supplies in current circulation.
An alternative brand of doxorubicin liposomal, Lipodox® (doxorubicin liposomal) injection is available to patients under the Special Access Scheme (SAS) as it is not yet registered in Australia. HPS Pharmacies can offer immediate supply to Category A, seriously ill patients, pending completion and forwarding of the Category A SAS form by the medical practitioner.
The PBS has made an unprecedented response to public need by listing Lipodox® injection in advance of its registration. It requires an Authority prescription and offers doses of 20mg/10mL and 50mg/25mL, equivalent to Caelyx® injection.
Clinicians are reminded that conventional doxorubicin hydrochloride is not dose equivalent on a milligram-per-milligram basis to doxorubicin liposomal.
Please retain this notice in a prominent position, including other related business units as a reminder for all staff members until supply returns to normal.
Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please do not hesitate to contact your pharmacist at HPS Pharmacies or Janssen-Cilag Medical Information on 1800 225 334. Medical Information enquiries and adverse event reports regarding Lipodox® can be made to Sun Pharmaceuticals on 1800 267 356.
Information regarding expected dates for supply may vary subject to delays which are out of our control. HPS Pharmacies does not accept responsibility for such changes but will endeavour to keep our clients updated as information is made available from drug manufacturers or wholesalers.